Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Dana E Rathkopf; Steven M Larson; Aseem Anand; Michael J Morris; Susan F Slovin; David R Shaffer; Glenn Heller; Brett Carver; Neal Rosen; Howard I Scher

doi:10.1002/cncr.29578

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Dana E Rathkopf, Steven M Larson, Aseem Anand, Michael J Morris, Susan F Slovin, David R Shaffer, Glenn Heller, Brett Carver, Neal Rosen, Howard I Scher

Urological cancer, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).

Original language	English
Pages (from-to)	3853-3861
Journal	Cancer
Volume	121
Issue number	21
DOIs	https://doi.org/10.1002/cncr.29578
Publication status	Published - 2015

Subject classification (UKÄ)

Urology and Nephrology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.29578

http://www.ncbi.nlm.nih.gov/pubmed/26178426?dopt=Abstract

Cite this

@article{4c5f3dbc1bd0459e89d1c90787e1708d,

title = "Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.",

abstract = "The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).",

author = "Rathkopf, {Dana E} and Larson, {Steven M} and Aseem Anand and Morris, {Michael J} and Slovin, {Susan F} and Shaffer, {David R} and Glenn Heller and Brett Carver and Neal Rosen and Scher, {Howard I}",

year = "2015",

doi = "10.1002/cncr.29578",

language = "English",

volume = "121",

pages = "3853--3861",

journal = "Cancer",

issn = "1097-0142",

publisher = "John Wiley & Sons Inc.",

number = "21",

}

TY - JOUR

T1 - Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

AU - Rathkopf, Dana E

AU - Larson, Steven M

AU - Anand, Aseem

AU - Morris, Michael J

AU - Slovin, Susan F

AU - Shaffer, David R

AU - Heller, Glenn

AU - Carver, Brett

AU - Rosen, Neal

AU - Scher, Howard I

PY - 2015

Y1 - 2015

N2 - The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).

AB - The effects of mammalian target of rapamycin (mTOR) inhibition are limited by feedback reactivation of receptor tyrosine kinase signaling in phosphatase and tensin homolog-null tumors. Thus, this study tested the combination of mTOR inhibition (everolimus) and epidermal growth factor receptor inhibition (gefitinib) in castration-resistant prostate cancer (CRPC).

U2 - 10.1002/cncr.29578

DO - 10.1002/cncr.29578

M3 - Article

C2 - 26178426

SN - 1097-0142

VL - 121

SP - 3853

EP - 3861

JO - Cancer

JF - Cancer

IS - 21

ER -

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this